Array BioPharma Inc. (NASDAQ: ARRY) today announced positive dose-escalation/expansion data for its novel, small molecule dual p38/Tie2 inhibitor, ARRY-614. The data were presented at the 2011 Annual Meeting of the American Society of Hematology (ASH) in San Diego, California. ARRY-614 demonstrated clinical activity as measured by hematologic improvement (increased neutrophils, platelets and/or red blood cells) in patients with myelodysplastic syndromes (MDS) and was generally well tolerated. Today's presentation slides are summarized below and PDF versions are available for download on Array's website at www.arraybiopharma.com.
"I am excited about the results of the Phase 1 study with ARRY-614, which was well-tolerated in lower risk MDS patients," said Rami S. Komrokji, M.D., Clinical Director, Hematologic Malignancies, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Fla. "I am particularly encouraged with the multi-lineage hematological responses observed. Responses were seen in patients for whom hypomethylating agents had failed, a group with no available treatment options. I look forward to the upcoming trial with the new formulation of ARRY-614."